DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TYSABRI (natalizumab)
*****************************************************
#Post#: 647--------------------------------------------------
(Abst.) Tysabri not so effective if you're over 50
By: agate Date: February 10, 2015, 3:09 pm
---------------------------------------------------------
From Multiple Sclerosis Journal, February 10, 2015:
[quote]Age-dependent effects on the treatment response of
natalizumab in MS patients
Henrik Matell
Karolinska University Hospital, Sweden
Jan Lycke
Sahlgrenska University Hospital, Sweden
Anders Svenningsson
Clinical Neuroscience, Umeĺ University, Sweden
Carolina Holmén
Karolinska University Hospital, Sweden
Mohsen Khademi
Karolinska University Hospital, Sweden
Jan Hillert
Karolinska University Hospital, Sweden
Tomas Olsson
Karolinska University Hospital, Sweden
Fredrik Piehl
Karolinska University Hospital, Sweden
Karolinska University Hospital, R03:04, S171 76 Stockholm,
Sweden. henrik.matell@karolinska.se
Background:
Natalizumab is approved for treatment of active forms of
relapsing–remitting multiple sclerosis (MS) based on a pivotal
phase III study comprising patients aged 18–50 years. The effect
of natalizumab has not been specifically studied in older
patients.
Objective:
We analyzed age-dependent effects on treatment-related outcome
measures in 1872 patients, 189 of whom were aged 50 or more,
included in the Swedish post-marketing natalizumab surveillance
program.
Methods:
In three MS centers registry data for patients aged >50 years
were validated.
Results:
At baseline older patients had longer disease duration, higher
Expanded Disability Status Scale (EDSS) and lower Symbol Digit
Modality Test (SDMT) scores than younger patients. The influence
from natalizumab on outcome measures was significantly reduced
and 18.7% of patients >50 years stopped treatment for lack of
effect compared to 7.7% in the younger age group. At baseline,
the cerebrospinal fluid levels of the chemokine CXCL13 and the
leukocyte cell count were negatively correlated with age in a
smaller subgroup of patients.
Conclusion:
These results were in agreement with previous findings
suggesting that inflammation is more pronounced in younger
patients and therefore the beneficial effects of potent
anti-inflammatory treatments are subsiding with older
ages.[/quote]
The abstract can be seen here
HTML http://msj.sagepub.com/content/21/1/48?etoc.
*****************************************************